How much funding has Coultreon Biopharma raised?

Coultreon Biopharma has raised $125.0M in total funding, most recently a Series A round.

When was Coultreon Biopharma founded?

Coultreon Biopharma was founded in 2025.

Where is Coultreon Biopharma headquartered?

Coultreon Biopharma is headquartered in Leuven, United States.

What industry is Coultreon Biopharma in?

Coultreon Biopharma operates in Biotech.

How many employees does Coultreon Biopharma have?

Coultreon Biopharma has 11-50 employees.

Coultreon Biopharma

Q: Who are Coultreon Biopharma's investors?

Coultreon Biopharma's investors include Sofinnova Investments, Forbion Capital Partners, Novo Holdings A/S, Regeneron Pharmaceuticals.

Transforming lives with groundbreaking treatments

Leuven, United States · Founded 2025 · $125.0M raised

Biotech

Headquarters: Leuven
Employees: 11–50
Founded: 2025
Business Model: B2B

Website: coultreon.com
Total Funding: $125.0M
Last Round: $125.0M Series AApr 2026
Rounds: 1

About

Coultreon Biopharma (formerly Onco3R Therapeutics) is a Leuven, Belgium-based clinical-stage biotech founded in 2025 developing precision medicines for autoimmune and inflammatory diseases. Its lead asset COL-5671 is a selective SIK3 inhibitor that completed Phase 1 with favorable safety and pharmacokinetic data, targeting ulcerative colitis and other immune-mediated conditions with a once-daily oral therapy.

Summary

Coultreon Biopharma is a Biotech company based in Leuven, United States, founded in 2025. It has raised $125.0M in total across 1 round, most recently a $125.0M Series A round in Apr 2026. Investors include Sofinnova Investments, Forbion Capital Partners and Novo Holdings A/S.